Drugs / Alpharix-Tetra®
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT06602024 Comparator | Sep 2024 → Aug 2025 | influenza | ModernaTX, Inc. | Completed | Met primary |
| Phase 4 | NCT06716567 Comparator | Nov 2020 → Nov 2023 | influenza | Centre Hospitalier Universitaire Saint Pierre | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alpharix Tetra | “Alpharix-Tetra®, Vaxigrip Tetra® and Influvac Tetra® were used as influenza vaccines in the 2020-2021, 2021-2022, and 2022-2023 seasons respectively.” NCT06716567 ↗ |
| Modality | Vaccine | “Participants will receive a single injection of active comparator trivalent influenza vaccine (TIV) or quadrivalent influenza vaccine (QIV) (Fluarix®, Fluarix Tetra,...” NCT06602024 ↗ |